Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• CD5-positive (CD5(+)) diffuse large B-cell lymphoma (DLBCL) is associated with poor prognosis and frequent central nervous system (CNS) relapse.
• The role of CD5 expression in DLBCL, particularly its relationship with molecular subtypes and clinical outcomes, requires further elucidation.

Purpose of the Study:

• To investigate the gene expression profile of CD5(+) DLBCL.
• To identify molecular differences and similarities between CD5(+) and CD5-negative (CD5(-)) DLBCL.
• To explore potential therapeutic strategies and the mechanisms underlying CNS relapse in CD5(+) DLBCL.

Main Methods:

• Gene expression profiling using Agilent human oligo microarrays on RNA from 90 DLBCL patients (33 CD5(+) and 57 CD5(-)).
• Supervised analysis and gene expression classifiers to identify CD5 expression patterns.
• Gene Ontology (GO) enrichment analysis to understand functional pathways associated with CD5(+) DLBCL.

Main Results:

• All 33 CD5(+) DLBCL cases were classified as activated B-cell-like (ABC) DLBCL.
• A gene expression classifier accurately identified CD5 expression in DLBCL and ABC DLBCL subtypes.
• The gene SH3BP5 was identified as most relevant to CD5 expression.
• Enriched GO categories in CD5(+) ABC DLBCL included multicellular organismal signaling, nerve impulse transmission, and synaptic transmission.

Conclusions:

• CD5(+) DLBCL predominantly belongs to the ABC DLBCL subtype.
• Therapeutic strategies targeting ABC DLBCL may be effective for CD5(+) DLBCL.
• The identified gene signature and enriched pathways offer insights into the high incidence of CNS relapse in CD5(+) DLBCL.